AstraZeneca (LON:AZN) Given a £110 Price Target by Credit Suisse Group Analysts

Credit Suisse Group set a £110 ($134.79) price objective on AstraZeneca (LON:AZNGet Rating) in a research note issued to investors on Monday morning, Borsen Zeitung reports.

AZN has been the subject of a number of other reports. set a £120 ($147.04) price target on shares of AstraZeneca in a research report on Monday. Jefferies Financial Group set a GBX 9,800 ($120.08) price target on shares of AstraZeneca in a research report on Thursday, July 7th. UBS Group set a £101 ($123.76) price target on shares of AstraZeneca in a research note on Tuesday, June 14th. JPMorgan Chase & Co. set a £120 ($147.04) target price on shares of AstraZeneca in a research note on Wednesday, July 13th. Finally, Deutsche Bank Aktiengesellschaft set a £115 ($140.91) price target on shares of AstraZeneca in a research note on Thursday, July 14th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of Buy and an average target price of £106.54 ($130.55).

AstraZeneca Trading Up 0.5 %

LON AZN opened at £107.20 ($131.36) on Monday. The company has a current ratio of 0.96, a quick ratio of 0.67 and a debt-to-equity ratio of 87.31. The company has a fifty day simple moving average of £106.05 and a two-hundred day simple moving average of GBX 9,965.42. AstraZeneca has a 12-month low of GBX 8,029 ($98.38) and a 12-month high of £112.90 ($138.34). The stock has a market cap of £166.11 billion and a P/E ratio of -182.31.

AstraZeneca Cuts Dividend

The firm also recently declared a dividend, which will be paid on Monday, September 12th. Shareholders of record on Thursday, August 11th will be paid a GBX 76.40 ($0.94) dividend. This represents a yield of 0.7%. The ex-dividend date is Thursday, August 11th. AstraZeneca’s dividend payout ratio (DPR) is presently -377.55%.

About AstraZeneca

(Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Featured Articles

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.